J. Schapiro

发表

2022 update of the drug resistance mutations in HIV-1.

D. Richman, A. Wensing, F. Ceccherini‐Silberstein, 2022, Topics in antiviral medicine.

Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells.

T. Merigan, J. Schapiro, C. Gray, 2000, AIDS research and human retroviruses.

HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance.

Tommy F. Liu, R. Shafer, J. Schapiro, 2005, The Journal of infectious diseases.

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

S. Hammer, M. Hirsch, D. Richman, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Update of the drug resistance mutations in HIV-1: December 2010.

D. Richman, H. Günthard, V. Johnson, 2010, Topics in HIV medicine : a publication of the International AIDS Society, USA.

European guidelines on the clinical management of HIV-1 tropism testing.

A. Wensing, H. Walter, R. Kaiser, 2011, The Lancet. Infectious diseases.

Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333.

J. Schapiro, C. Boucher, V. DeGruttola, 2000, The Journal of infectious diseases.

HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms.

B. J. Betts, R. Shafer, F. Brun-Vézinet, 2003, Journal of acquired immune deficiency syndromes.

Human Immunodeficiency Virus Type 1 Protease Genotypes and In Vitro Protease Inhibitor Susceptibilities of Isolates from Individuals Who Were Switched to Other Protease Inhibitors after Long-Term Saquinavir Treatment

T. Merigan, J. Schapiro, J. Lawrence, 1998, Journal of Virology.

Update of the drug resistance mutations in HIV-1: 2007.

D. Richman, H. Günthard, V. Johnson, 2007, Topics in HIV medicine : a publication of the International AIDS Society, USA.

HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Robert W Shafer, R. Shafer, J. Schapiro, 2008, AIDS reviews.

Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV

D. Kuritzkes, J. Schapiro, P. Cahn, 2022, HIV medicine.

In memoriam: Charles Boucher (1958‐2021)

J. Schapiro, P. Reiss, A. Sohn, 2021, Journal of the International AIDS Society.

Integrase as a Novel Target for the Inhibition of Human Immunodeficiency Virus Type 1 Infection: Current Status and Future Perspectives

J. Schapiro, A. Voet, Z. Debyser, 2009 .

Localization of a gene causing cystinuria to chromosome 2p

J. Weissenbach, J. Schapiro, D. Kastner, 1994, Nature Genetics.

Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229.

B. Efron, T. Merigan, J. Schapiro, 1999, The Journal of infectious diseases.

Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real‐world data

J. Schapiro, G. Kenet, A. Lubetsky, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing

H. Walter, R. Kaiser, K. Korn, 2010, Journal of the International AIDS Society.

Economic Evaluation of Drug Resistance Genotyping for the Adaptation of Treatment in HIV‐Infected Patients in the VIRADAPT Study

J. Schapiro, I. Durand-zaleski, P. Clevenbergh, 2000, Journal of acquired immune deficiency syndromes.

Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.

J. Schapiro, A. De Luca, R. Hamers, 2013, The Journal of infectious diseases.

Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations

B. Clotet, J. Schapiro, V. Soriano, 2004, AIDS.

Survival of hepatitis C-infected haemophilia patients is predicted by presence of cirrhosis but not by anti-viral treatment.

J. Schapiro, Y. Maor, D. Bashari, 2014, Annals of hepatology.

Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection

J. Schapiro, P. Reiss, D. Burger, 2015, Expert opinion on drug safety.

Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C‐infected haemophilia patients

J. Schapiro, Y. Maor, G. Kenet, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Typhoid fever in Ethiopian immigrants to Israel and native-born Israelis: a comparative study.

J. Schapiro, Y. Carmeli, R. Raz, 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Receiving Highly Active Antiretroviral T Cells in Individuals + Anti-HIV CD 8 Frequency of Class I HLA-Restricted

Mark M. Davis, J. Schapiro, C. Gray, 1999 .

Genetic polymorphism of IL28B in hepatitis C‐infected haemophilia patients in Israel

J. Schapiro, Y. Maor, D. Bashari, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Hepatitis C at the Israeli National Hemophilia Center

J. Schapiro, Y. Maor, G. Kenet, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

In Vitro Antiviral Activity and Cross-Resistance Proﬁle of PL-100, a Novel Protease Inhibitor of Human Immunodeﬁciency Virus Type 1 (cid:1)

M. Wainberg, J. Schapiro, N. Parkin, 2007 .

Natural killer (NK) cell response after vaccination of volunteers with killed influenza vaccine

J. Schapiro, Y. Segev, B. Rager-Zisman, 1990, Journal of medical virology.

A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study.

B. Clotet, J. Schapiro, J. Gatell, 2008, The Journal of antimicrobial chemotherapy.

Drug development strategies for salvage therapy: conflicts and solutions.

M. J. van der Laan, D. Kuritzkes, J. Schapiro, 2006, AIDS research and human retroviruses.

A Call for a Consortium for Optimal Management of Drug–Drug Interactions in Patient Care

J. Schapiro, D. Back, D. Burger, 2017, Clinical pharmacology and therapeutics.

Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C

J. Schapiro, Z. Grossman, D. Averbuch, 2004, AIDS.

Lymph node human immunodeficiency virus RNA levels and resistance mutations in patients receiving high-dose saquinavir.

T. Merigan, J. Schapiro, M. Vierra, 1998, The Journal of infectious diseases.

Treatment of hepatitis C in patients with haemophilia – the Israeli National Hemophilia Center experience

J. Schapiro, Y. Maor, D. Bashari, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Survey in Israel and Analytic Review

J. Schapiro, Y. Carmeli, A. Yinnon, 2016 .

Streptococcal group C bacteremia. Survey in Israel and analytic review.

J. Schapiro, Y. Carmeli, A. Yinnon, 1995, Archives of internal medicine.

Erythromycin Base-Induced Rash and Liver Function Disturbances

J. Schapiro, N. Arber, H. Shirin, 1992, The Annals of pharmacotherapy.

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

S. Hammer, M. Hirsch, D. Richman, 2000, Topics in HIV medicine : a publication of the International AIDS Society, USA.

The Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected Patients

Bradley Efron, B. Efron, T. Merigan, 1996, Annals of Internal Medicine.

Therapeutic Drug Monitoring

J. Schapiro, C. Boucher, R. Aarnoutse, 2012, Drugs.

Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing

JD Lundgren, N Clumeck, A. D. Luca, 2004, Antiviral therapy.

Updated guideline to perform therapeutic drug monitoring for antiretroviral agents.

J. Schapiro, C. Flexner, T. Blaschke, 2006 .

Therapeutic Drug Monitoring

J. Schapiro, C. Boucher, R. Aarnoutse, 2012, Drugs.

Drug resistance mutations in HIV-1.

R. Shafer, D. Richman, V. Johnson, 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Antiretroviral Drug Resistance in Non-Subtype B HIV-1, HIV-2 and Siv

J. Schapiro, N. Parkin, Jonathan M Schapiro, 2004, Antiviral therapy.

Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B

Zehava Grossman, Zvi Bentwich, Jonathan M. Schapiro, 2001, AIDS (London).

Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs

Matthew J. Gonzales, Robert W. Shafer, Rami Kantor, 2001, Nucleic Acids Res..

Update of the Drug Resistance Mutations in HIV-1: December 2008

Deenan Pillay, Victoria A Johnson, Francoise Brun-Vezinet, 2008 .

Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach

J. Schapiro, D. Back, M. Lamorde, 2014, AIDS.

Update of the drug resistance mutations in HIV-1: Spring 2008.

Huldrych F Günthard, Deenan Pillay, Victoria A Johnson, 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).

T. Merigan, J. Schapiro, C. Gray, 1999, Journal of immunology.

Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration

Lynn Morris, Anne-Mieke Vandamme, Praphan Phanuphak, 2005, PLoS medicine.

Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation

Philip L. Tzou, D. Katzenstein, R. Shafer, 2017, PloS one.

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration

Huldrych F. Günthard, Dominique Goedhals, Susan P. Holmes, 2017, EBioMedicine.

Update of the drug resistance mutations in HIV-1: Fall 2006.

Deenan Pillay, Victoria A Johnson, Francoise Brun-Vezinet, 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir

Jonathan M. Schapiro, J. Schapiro, C. Boucher, 2006, Journal of Virology.

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

D. Kuritzkes, J. Schapiro, J. Polli, 2021, AIDS.

Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.

B. Clotet, J. Schapiro, J. Llibre, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection

Catia Marzolini, Saye H. Khoo, David M. Burger, 2017, PloS one.

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

J. Schapiro, P. Clevenbergh, P. Halfon, 2000, AIDS.

Improving the Prediction of Virological Response to Tipranavir: The Development and Validation of a Tipranavir-Weighted Mutation Score

J. Schapiro, C. Boucher, C. Perno, 2010, Antiviral therapy.

Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study.

J. Schapiro, I. Durand-zaleski, P. Clevenbergh, 2000 .

Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update

Anne-Mieke Vandamme, Soo-Yon Rhee, Tommy F. Liu, 2009, PloS one.

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.

Philip L. Tzou, R. Shafer, P. Harrigan, 2019, The Journal of antimicrobial chemotherapy.

A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors

M. Wainberg, J. Schapiro, B. Brenner, 2003, AIDS.

HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance

Soo-Yon Rhee, Paul Sandstrom, Deenan Pillay, 2007, AIDS.

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

Lidia Ruiz, Bonaventura Clotet, B. Clotet, 2002, AIDS.

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing

T. F. Rinke de Wit, D. Katzenstein, R. Shafer, 2015, PloS one.

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

D. Katzenstein, N. Ford, R. Shafer, 2013, The Journal of infectious diseases.

Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.

B. Clotet, J. Schapiro, S. Moreno, 2007, The Journal of antimicrobial chemotherapy.

Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.

Michael I. Jordan, S. Delany-Moretlwe, R. Paredes, 2023, The lancet. HIV.

Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort.

J. Schapiro, M. Zolfo, L. Lynen, 2011, AIDS research and human retroviruses.

Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of South African adult patients on second‐line ART

A. Wensing, J. Schapiro, E. V. van Maarseveen, 2020, Journal of the International AIDS Society.

Mutation D30N Is Not Preferentially Selected by Human Immunodeficiency Virus Type 1 Subtype C in the Development of Resistance to Nelfinavir

Dan Engelhard, Zehava Grossman, Ella Mendelson, 2004, Antimicrobial Agents and Chemotherapy.

The Influence of Protease Inhibitor Resistance Profiles on Selection of HIV Therapy in Treatment-Naive Patients

M. Wainberg, J. Schapiro, B. Brenner, 2003, Antiviral therapy.

Long-term control of HIV replication with dolutegravir and pegylated interferon alpha-2a in an HIV-infected patient with sixtuple-class resistance.

J. Schapiro, J. Arribas, S. García-Bujalance, 2014, AIDS.

Cure of chronic hepatitis C virus infection in an HIV-coinfected patient with multiple comorbidities and drug interaction challenges

J. Schapiro, S. Khoo, S. Bhagani, 2018, International journal of STD & AIDS.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns

Victor DeGruttola, Vincent Calvez, Maurizio Zazzi, 2004, Antiviral therapy.

Update of the drug resistance mutations in HIV-1: Fall 2005.

Amalio Telenti, Deenan Pillay, Victoria A Johnson, 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Diminished Selection for Thymidine-Analog Mutations Associated With the Presence of M184V in Ethiopian Children Infected With HIV Subtype C Receiving Lamivudine-Containing Therapy

J. Schapiro, Z. Grossman, D. Engelhard, 2006, The Pediatric infectious disease journal.

Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent

Lynn Morris, Anne-Mieke Vandamme, Praphan Phanuphak, 2006, Antimicrobial Agents and Chemotherapy.

HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes

Lynn Morris, Soo-Yon Rhee, Rami Kantor, 2006, AIDS.

Drug resistance mutations in HIV-1.

Amalio Telenti, Deenan Pillay, Victoria A Johnson, 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.

D rug-resistance genotyping in HIV-1 t h e r a py : the VIRAD A P T randomised controlled trial

J. Schapiro, P. Clevenbergh, P. Halfon, 2022 .

Evolution of Primary Protease Inhibitor Resistance Mutations during Protease Inhibitor Salvage Therapy

Robert W. Shafer, Rami Kantor, Jonathan M. Schapiro, 2002, Antimicrobial Agents and Chemotherapy.

Drug resistance and antiretroviral drug development.

Robert W Shafer, R. Shafer, J. Schapiro, 2005, The Journal of antimicrobial chemotherapy.

Role of drug susceptibility testing during pre-clinical drug development

R. Shafer, J. Schapiro, 2005 .

Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens.

B. Clotet, J. Schapiro, A. Ornelas, 2012, The Journal of antimicrobial chemotherapy.

A systematic review of adeno‐associated virus gene therapy clinical trials for HIV – A potential solution for patients with haemophilia and HIV?

E. Klang, J. Schapiro, S. Soffer, 2023, Haemophilia : the official journal of the World Federation of Hemophilia.

Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV‐infected patients experiencing prolonged virologic failure

Carlos Toro, J. Schapiro, B. Rodés, 2004, Journal of medical virology.

Immigration of Ethiopians with typhoid fever to Israel: apparent lack of influence on the local population.

J. Schapiro, Y. Carmeli, M. Alkan, 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

OP-JANM190417 1..13

Philip L. Tzou, R. Shafer, P. Harrigan, 2019 .

Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching

R. Shafer, B. Clotet, J. Schapiro, 2008, AIDS.

Update of the drug resistance mutations in HIV-1: 2004.

Amalio Telenti, Deenan Pillay, Victoria A Johnson, 2004, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.

T. Merigan, J. Schapiro, C. Gray, 1998, AIDS research and human retroviruses.

Baseline CD4+ T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients

D. Kuritzkes, J. Schapiro, C. Boucher, 2011, Antiviral therapy.

Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV‐1‐infected patients with multidrug‐resistant virus: a multicentre pilot study

J. Schapiro, J. Martinez-Picado, E. Negredo, 2008, HIV medicine.

Drug‐induced and traumatic nail problems in the haemophilias

J. Schapiro, M. Wershavski, U. Martinowitz, 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

Prosthetic valve endocarditis due to Legionella pneumophila.

J. Schapiro, J. Loutit, T. T. Chen, 1996, The Journal of cardiovascular surgery.

Comparable Long-Term Efficacy of Lopinavir/Ritonavir and Similar Drug-Resistance Profiles in Different HIV-1 Subtypes

J. Schapiro, Z. Grossman, H. Rudich, 2014, PloS one.

Patient compliance and drug failure in protease inhibitor monotherapy.

T F Blaschke, T. Merigan, J. Schapiro, 1996, JAMA.

Update of the Drug Resistance Mutations in HIV-1: 2005.

Amalio Telenti, Victoria A Johnson, Francoise Brun-Vezinet, 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons.

B. Efron, T. Merigan, J. Schapiro, 1999, The Journal of infectious diseases.

Nucleic acid differences between HIV-1 non-B and B reverse transcriptase and protease sequences at drug resistance positions

Soriano, D. Katzenstein, R. Shafer, 2003 .

Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.

T. Merigan, J. Schapiro, J. Lawrence, 1999, AIDS.

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance

R. Shafer, J. Schapiro, S. Khoo, 2023, AIDS Research and Therapy.

Potential Role of Doravirine for the Treatment of Patients with Transmitted Drug Resistance

J. Schapiro, S. Rhee, Soo-Yon Rhee, 2022 .

In Vitro Antiviral Activity and Cross-Resistance Profile of PL-100, a Novel Protease Inhibitor of Human Immunodeficiency Virus Type 1

M. Wainberg, J. Schapiro, N. Parkin, 2007, Antimicrobial Agents and Chemotherapy.

Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors are subtype dependent

Lynn Morris, Anne-Mieke Vandamme, Praphan Phanuphak, 2004 .

Connection Domain Mutations in HIV-1 Reverse Transcriptase Do Not Impact Etravirine Susceptibility and Virologic Responses to Etravirine-Containing Regimens

R. Paredes, B. Clotet, J. Schapiro, 2011, Antimicrobial Agents and Chemotherapy.

Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis

J. Schapiro, L. Leibovici, M. Paul, 2010, European Journal of Clinical Microbiology & Infectious Diseases.

Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial

J. Schapiro, C. Boucher, C. Boucher, 1999, The Lancet.

Platelet hyperreactivity and prognosis in survivors of myocardial infarction.

J. Schapiro, M. Trip, F. V. Van Capelle, 1990, The New England journal of medicine.

Pacemaker endocarditis. Report of 44 cases and review of the literature.

I. Lossos, J. Schapiro, N. Arber, 1994, Medicine.

Persisting Long-Term Benefit of Genotype-Guided Treatment for HIV-Infected Patients Failing Haart. The Viradapt Study: Week 48 Follow-Up

J. Schapiro, C. Boucher, C. Boucher, 2000, Antiviral therapy.

Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.

D. Kuritzkes, J. Schapiro, J. Polli, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Update of the drug resistance mutations in HIV-1: 2004.

D. Richman, A. Telenti, V. Johnson, 2004, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Update of the Drug Resistance Mutations in HIV-1: 2005.

D. Richman, A. Telenti, V. Johnson, 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Update of the drug resistance mutations in HIV-1: December 2009.

D. Richman, V. Johnson, B. Clotet, 2009, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Update of the Drug Resistance Mutations in HIV-1.

H. Gunthard, J. Schapiro, Victoria A. Johnson, 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Antiretroviral Drug Resistance Testing in Adult Hiv-1 Infection: 2008 Recommendations of an International Aids Society–usa Panel

S. Hammer, D. Richman, V. Johnson, 2022 .

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

H. Günthard, J. Schapiro, J. Mellors, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.

B. Clotet, J. Schapiro, J. Llibre, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.